Economic evaluations of hepatitis B vaccination for developing countries

Expert Review of Vaccines

Volumn 8, Issue 7, 2009, Pages 907-920

  Tu, Hong Anh T ^a   Woerdenbag, Herman J ^a   Kane, Sumit ^b   Riewpaiboon, Arthorn ^c   Van Hulst, Marinus ^a,d,e   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ROYAL TROPICAL INSTITUTE   (Netherlands)

^c MAHIDOL UNIVERSITY   (Thailand)

^d MARTINI HOSPITAL   (Netherlands)

^e Health Economics Consultancy and Technology Assessments (HECTA)   (Netherlands)

Author keywords

Developing country; Health economic study; Hepatitis B vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN;

COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEVELOPING COUNTRY; DIPHTHERIA; DRUG CHOICE; DRUG COST; ENDEMIC DISEASE; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MASS SCREENING; OUTCOME ASSESSMENT; POLIOMYELITIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMATIC REVIEW; TETANUS; VACCINATION;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HEPATITIS B; HEPATITIS B VACCINES; HUMANS;

EID: 67650466150     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.53     Document Type: Review

References (36)

1. Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J. Hepatol. 38(2), 215-222 (2003). (Pubitemid 36169632)
2. Vimolket T, Poovorawan Y. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness. Southeast Asian J. Trop. Med. Public Health 36(3), 693-699 (2005). (Pubitemid 41316796)
3. Liu ZG, Zhao SL, Zhang YX. Cost-benefit ana lysis on immunization of newborns with hepatitis B vaccine in Jinan City. Chin. J. Epidemiol. 16, 81-84 (1995).
4. Hu R, Cao W, Zhang X: Cost-effectiveness ana lysis of hepatitis B vaccination in People's Liberation Army. Zhonghua Liu Xing Bing Xue Za Zhi 22(2), 142-145 (2001).
5. WHO. Western Pacific Regional Plan For Hepatitis B Control Through Immunization. WHO, Geneva, Switzerland (2007).
6. Sahni M, Jindal K, Abraham N, Aruldas K, Puliyel JM. Hepatitis B immunization: cost calculation in a community-based study in India. Indian J. Gastroenterol. 23(1), 16-18 (2004). (Pubitemid 38477967)
7. Prakash C. Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India. Int. J. Technol. Assess. Health Care 19(1), 28-40 (2003). (Pubitemid 36356325)
8. Kim SY, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull. World Health Organ. 85(11), 833-842 (2007). (Pubitemid 350086455)
9. Griffiths UK, Hutton G, Das Dores PE. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. Health Policy Plan 20(1), 50-59 (2005). (Pubitemid 40313198)
10. Edmunds W, Dejene A, Mekonnen Y, Haile M, Alemnu W, Nokes D. The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa. Health Policy Plan 15(4), 408-416 (2000). • Economic ana lysis from a respected research group.
11. Hall AJ, Roberston RL, Crivelli PE et al. Cost-effectiveness of hepatitis B vaccine in the Gambia. Trans. R. Soc. Trop. Med. Hyg. 87(3), 333-336 (1993).
12. Adibi P, Rezailashkajani M, Roshandel D et al. An economic ana lysis of premarriage prevention of hepatitis B transmission in Iran. BMC Infect. Dis. 4, 31 (2004). (Pubitemid 39637296)
13. WHO. Regional Strategic Plan for the Expanded Programme on Immunization, 2006-2009. WHO, Geneva, Switzerland (2006).
14. Mulley AG, Silverstein MD, Dienstag JL. Indications for use of hepatitis B vaccine, based on cost-effectiveness ana lysis. N. Engl. J. Med. 126, 716-721 (1982).
15. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J. Med. Virol. 67(3), 433-439 (2002).
16. Prakash C, Sharma RS, Bhatia R, Verghese T, Datta KK. Prevalence of North India of hepatitis B carrier state amongst pregnant women. Southeast Asian J. Trop. Med. Public Health 29(1), 80-84 (1998). (Pubitemid 128528940)
17. Van Damme P, Kane M, Andre M. Integration of hepatitis B vaccination into national immunization programmes. Br. Med. J. 314(7086) 1033-1037 (1997). (Pubitemid 27149766)
18. Hudeckova H, Straka S, Szilagyiova M, Avdicova M, Rusnakova S: Cost effectiveness and cost benefit of viral hepatitis B vaccination in the Slovak Republic. Cent. Eur. J. Public Health 10(4), 146-148 (2002). (Pubitemid 35477449)
19. Adam T, Baltussen R, Tan Torres T et al. Making choices in health: WHO guide to cost-effectiveness ana lysis. WHO, Geneva, Switzerland (2003). • WHO's point of view on cost-effectiveness.
20. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ. 10(8), 751-774 (2001). • Excellent overview of hepatitis B vaccination economic evaluations.
21. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes. Pharmacoeconomics 26(3), 191-215 (2008).
22. World Bank. Investing in health. Washington, DC, World Bank (1993).
23. WHO. Core Information for the Development of Immunization Policy: 2002 Update. WHO, Geneva, Switzerland (2002).
24. Kretzschmar M, Mangen MJ, van de Laar M, de Wit A. Model based analysis of hepatitis B vaccination strategies in The Netherlands. Vaccine 27(8), 1254-1260 (2009). • Dynamic modeling underlying cost-effectiveness assessment.
25. Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost effectiveness ana lysis. Health Econ. 10, 581-594 (2001). • Landmark study on discounting in health-economic ana lysis.
26. Parsonage M, Neuburger H. Discounting and health benefits. Health Econ. 1, 71-76 (1992).
27. Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J. Health Serv. Res. Policy 10(4), 245-250 (2005).
28. FitzSimons D, Van Damme P. Prevention and control of hepatitis B in central and eastern Europe and the newly independent states, Siofok, Hungary, 6-9 October 1996. Vaccine 15, 1595-1597 (1997).
29. Van Damme P, Vellinga A. Epidemiology of hepatitis B and C in Europe. Acta Gastro-Enterol. Belg. 61, 175-182 (1998).
30. Holliday SM, Faulds D. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. Pharmacoeconomics 5(2), 141-171 (1994).
31. Hepatitis-B fact sheet No. 204. WHO, Geneva, Switzerland (2000) www.who.int/media%20centre/fact%20sheet/fs%20164/en/
32. WHO. Hepatitis B vaccine. WHO, Geneva, Switzerland (2005) www.who.int/vaccines/en/hepatitisb.shtm/#strategies
33. WHO. Immunization, vaccines & biologicals. Hepatitis B www.who.int/immunization/topics/hepatitis-b/en/index.html
34. GAVI Alliance www.gavialliance.org
35. The World Bank. Data and statistics. Country groups http://web.worldbank. org/wbsite/external/datastatistics/0,,contentmdk:20421402~pa gepk:64133150~pipk:64133175~thesitepk:239419,00.html
36. WHO. Regional Office for the Western Pacific. Guidelines for certification of achievement of hepatitis B control goal in the Western Pacific region www.wpro.who.int/health-topics/hepatitis-b/